EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

Dermatology and Therapy

ISSN 2190-9172 · Springer Science and Business Media LLC

Latest articles

  1. Real-World Effectiveness of Risankizumab for Moderate-to-Severe Plaque Psoriasis by Sub-populations: Interim Analysis from VALUE at 37 Months

    Diamant Thaçi, Franca Wiemers, Charles W. Lynde, Mamitaro Ohtsuki, Luca Bianchi, Anne-Claire Fougerousse, Francisco Javier Garcia-Latasa de Aranibar, Simina Stefanescu, Spyridon Gkalpakiotis, Paul-Gunther Sator, Julia-Tatjana Maul, Andrea Szegedi, Paula C. Luna, Lynda Spelman, Simone Rubant, Tshepiso Madihlaba, Hongwei Wang, Doug Ashley, Kim A. Papp

    Published: 2026-11-06DOI: 10.1007/s13555-026-01954-0

  2. Treat-to-Target in Atopic Dermatitis: An Italian Survey and Expert Opinion on Clinical Practice and Unmet Needs

    Silvia Ferrucci, Marco Galluzzo, Mario Bruno Guanti, Katharina Hansel, Maddalena Napolitano, Eustachio Nettis, Michela Ortoncelli, Elena Pezzolo, Mariateresa Rossi, Alessandra Narcisi, Rosa Angileri, Ambrogio Francesca, Barbagallo Tania, Barei Francesca, Andrea Bassi, Francesco Bellinato, Alberto Bertoldi, Leonardo Bianchi, Tommaso Bianchelli, Giulia Calabrese, Paolo Calzari, Antonio Carpentieri, Francesca Caroppo, Marina Castriota, Cavaliere Giovanni, Lucia Ciampo, Francesco Cillo, Rosa Coppola, Pasquale Cozza, Mario De Lucia, Francesca Di Vico, Federico Diotiallevi, Marianna Donnarumma, Valeria Falcomatà, Carmen Fiorella, Nazzareno Gagliostro, Federica Gelato, Claudia Gioffrè, Serena Giacalone, Luigi Gargiulo

    Published: 2026-11-05DOI: 10.1007/s13555-026-01965-x

Volumes

2026 · 2912025 · 2492024 · 2422023 · 2222022 · 2052021 · 1732020 · 1222019 · 652018 · 602017 · 562016 · 642015 · 242014 · 252013 · 232012 · 172011 · 8

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.